Citations 2
Coccidioidomycosis in Patients Treated With Ruxolitinib
Kusne, Yael , Kimes, Kathryn E., Feller, Fionna , Patron, Roberto L. , Gea‐Banacloche, Juan , Blair, Janis E. , Vikram, Holenarasipur R. , Ampel, Neil M. , Feller, Fionna F, Patron, Roberto, Banacloche, Juan Gea, Vikram, Holenarasipur R.
Open Forum Infectious Diseases | June 10, 2020 | Volume: 7 | Issue: 6 | Pages: No page available
Abstract We report 8 cases of coccidioidomycosis associated with ruxolitinib treatment. Among 135 patients living in the coccidioidal-endemic region receiving ruxolitinib, 5 cases were diagnosed after starting and 4 had extrathoracic dissemination. Periodic serological screening while on ruxolitinib is warranted for patients residing in the coccidioidal-endemic region.
Pulmonary Coccidioidomycosis
Kimes, Kathryn E., Kasule, Sabirah N, Blair, Janis E.
Seminars in Respiratory and Critical Care Medicine | January 30, 2020 | Volume: 41 | Issue: 01 | Pages: 042-052
AbstractCoccidioidomycosis is an infection caused by the geographically restricted dimorphic fungus, Coccidioides. Coccidioidomycosis occurs endemically in the southwestern and western United States, mainly in focused regions of Arizona and California where the incidence is highest, and in Central and South America. Patients with impaired immunity, especially those with impaired cellular immunity, are at higher risk of severe and disseminated disease. In this review, we describe the fungal ecology and mycology, epidemiology, pathophysiology, and normal immune defenses to Coccidioides as well as address current concepts in diagnosis, treatment, and continued care of patients with pulmonary coccidioidomycosis. We also present and answer our most frequently asked questions regarding patients with primary pulmonary coccidioidomycosis.